|
| Public Act 100-0368
|
| HB2534 Enrolled | LRB100 08419 RLC 18533 b |
|
|
AN ACT concerning criminal law.
|
Be it enacted by the People of the State of Illinois,
|
represented in the General Assembly:
|
Section 5. The Illinois Controlled Substances Act is |
amended by changing Sections 204, 206, 208, 401, and 402 as |
follows:
|
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
Sec. 204. (a) The controlled substances listed in this |
Section are
included in Schedule I. |
(b) Unless specifically excepted or unless listed in |
another
schedule, any of the following opiates, including their |
isomers,
esters, ethers, salts, and salts of isomers, esters, |
and ethers,
whenever the existence of such isomers, esters, |
ethers and salts is
possible within the specific chemical |
designation: |
(1) Acetylmethadol; |
(1.1) Acetyl-alpha-methylfentanyl |
(N-[1-(1-methyl-2-phenethyl)-
|
4-piperidinyl]-N-phenylacetamide); |
(2) Allylprodine; |
(3) Alphacetylmethadol, except
|
levo-alphacetylmethadol (also known as levo-alpha-
|
acetylmethadol, levomethadyl acetate, or LAAM); |
|
(19) Dimepheptanol; |
(20) Dimethylthiambutene; |
(21) Dioxaphetylbutyrate; |
(22) Dipipanone; |
(23) Ethylmethylthiambutene; |
(24) Etonitazene; |
(25) Etoxeridine; |
(26) Furethidine; |
(27) Hydroxpethidine; |
(28) Ketobemidone; |
(29) Levomoramide; |
(30) Levophenacylmorphan; |
(31) 3-Methylfentanyl
|
(N-[3-methyl-1-(2-phenylethyl)-
|
4-piperidyl]-N-phenylpropanamide); |
(31.1) 3-Methylthiofentanyl
|
(N-[(3-methyl-1-(2-thienyl)ethyl-
|
4-piperidinyl]-N-phenylpropanamide); |
(32) Morpheridine; |
(33) Noracymethadol; |
(34) Norlevorphanol; |
(35) Normethadone; |
(36) Norpipanone; |
(36.1) Para-fluorofentanyl
|
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
4-piperidinyl]propanamide); |
|
(4-nitrophenyl)ethyl]-2-piperidinylidene]-
|
benzenesulfonamide (W-18); |
(56) 4-chloro-N-[1-(2-phenylethyl)
|
-2-piperidinylidene]-benzenesulfonamide (W-15); |
(57) acrylfentanyl (acryloylfentanyl). |
(c) Unless specifically excepted or unless listed in |
another
schedule, any of the following opium derivatives, its |
salts, isomers
and salts of isomers, whenever the existence of |
such salts, isomers and
salts of isomers is possible within the |
specific chemical designation: |
(1) Acetorphine; |
(2) Acetyldihydrocodeine; |
(3) Benzylmorphine; |
(4) Codeine methylbromide; |
(5) Codeine-N-Oxide; |
(6) Cyprenorphine; |
(7) Desomorphine; |
(8) Diacetyldihydromorphine (Dihydroheroin); |
(9) Dihydromorphine; |
(10) Drotebanol; |
(11) Etorphine (except hydrochloride salt); |
(12) Heroin; |
(13) Hydromorphinol; |
(14) Methyldesorphine; |
(15) Methyldihydromorphine; |
(16) Morphine methylbromide; |
|
(17) Morphine methylsulfonate; |
(18) Morphine-N-Oxide; |
(19) Myrophine; |
(20) Nicocodeine; |
(21) Nicomorphine; |
(22) Normorphine; |
(23) Pholcodine; |
(24) Thebacon. |
(d) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
hallucinogenic substances, or which
contains any of its salts, |
isomers and salts of isomers, whenever the
existence of such |
salts, isomers, and salts of isomers is possible
within the |
specific chemical designation (for the purposes of this
|
paragraph only, the term "isomer" includes the optical, |
position and
geometric isomers): |
(1) 3,4-methylenedioxyamphetamine
|
(alpha-methyl,3,4-methylenedioxyphenethylamine,
|
methylenedioxyamphetamine, MDA); |
(1.1) Alpha-ethyltryptamine
|
(some trade or other names: etryptamine;
|
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
3-(2-aminobutyl)indole; a-ET; and AET); |
(2) 3,4-methylenedioxymethamphetamine (MDMA); |
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
|
(also known as: N-ethyl-alpha-methyl-
|
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
and MDEA); |
(2.2) N-Benzylpiperazine (BZP); |
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP); |
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
(4) 3,4,5-trimethoxyamphetamine (TMA); |
(5) (Blank); |
(6) Diethyltryptamine (DET); |
(7) Dimethyltryptamine (DMT); |
(7.1) 5-Methoxy-diallyltryptamine; |
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
(9) Ibogaine (some trade and other names:
|
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
indole; Tabernanthe iboga); |
(10) Lysergic acid diethylamide; |
(10.1) Salvinorin A; |
(10.5) Salvia divinorum (meaning all parts of the plant |
presently classified
botanically as Salvia divinorum, |
whether growing or not, the
seeds thereof, any extract from |
any part of that plant, and every compound,
manufacture, |
salts, isomers, and salts of
isomers whenever the existence |
of such salts, isomers, and salts of
isomers is possible |
within the specific chemical designation, derivative, |
mixture, or preparation of that plant, its
seeds or |
|
extracts);
|
(11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
(12) Peyote (meaning all parts of the plant presently |
classified
botanically as Lophophora williamsii
Lemaire, |
whether growing or not, the
seeds thereof, any extract from |
any part of that plant, and every compound,
manufacture, |
salts, derivative, mixture, or preparation of that plant, |
its
seeds or extracts); |
(13) N-ethyl-3-piperidyl benzilate (JB 318); |
(14) N-methyl-3-piperidyl benzilate; |
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
(also known as N-hydroxy-alpha-methyl-
|
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
(15) Parahexyl; some trade or other names:
|
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
dibenzo (b,d) pyran; Synhexyl; |
(16) Psilocybin; |
(17) Psilocyn; |
(18) Alpha-methyltryptamine (AMT); |
(19) 2,5-dimethoxyamphetamine
|
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
(20) 4-bromo-2,5-dimethoxyamphetamine
|
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
4-bromo-2,5-DMA); |
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
Some trade or other names: 2-(4-bromo-
|
|
2,5-dimethoxyphenyl)-1-aminoethane;
|
alpha-desmethyl DOB, 2CB, Nexus; |
(21) 4-methoxyamphetamine
|
(4-methoxy-alpha-methylphenethylamine;
|
paramethoxyamphetamine; PMA); |
(22) (Blank); |
(23) Ethylamine analog of phencyclidine.
|
Some trade or other names:
|
N-ethyl-1-phenylcyclohexylamine,
|
(1-phenylcyclohexyl) ethylamine,
|
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
(24) Pyrrolidine analog of phencyclidine. Some trade |
or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
PHP; |
(25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
(26) 2,5-dimethoxy-4-ethylamphetamine
|
(another name: DOET); |
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
(another name: TCPy); |
(28) (Blank); |
(29) Thiophene analog of phencyclidine (some trade
|
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
2-thienyl analog of phencyclidine; TPCP; TCP); |
(29.1) Benzothiophene analog of phencyclidine Some |
trade or other names: BTCP or benocyclidine; |
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
|
(30) Bufotenine (some trade or other names:
|
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
3-(2-dimethylaminoethyl)-5-indolol;
|
5-hydroxy-N,N-dimethyltryptamine;
|
N,N-dimethylserotonin; mappine); |
(31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole |
Some trade or other names: JWH-018; |
(32) (Blank); 1-Butyl-3-(1-naphthoyl)indole |
Some trade or other names: JWH-073; |
(33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- |
(2-iodophenyl)methanone |
Some trade or other names: AM-694; |
(34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
(2-methyloctan-2-yl)phenol |
Some trade or other names: CP 47,497 |
and its C6, C8 and C9 homologs; |
(34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
(2-methyloctan-2-yl)phenol), where side chain n=5; |
and homologues where side chain n=4, 6, or 7; Some |
trade or other names: CP 47,497; |
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
(2-methyloctan-2-yl)-6a,7, |
10,10a-tetrahydrobenzo[c]chromen-1-ol |
Some trade or other names: HU-210; |
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
|
tetrahydrobenzo[c]chromen-1-ol, its isomers, |
salts, and salts of isomers; Some trade or other |
names: HU-210, Dexanabinol; |
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
6,6-dimethyl-3-(2-methyloctan-2-yl)- |
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
Some trade or other names: HU-211; |
(37) (Blank); (2-methyl-1-propyl-1H-indol- |
3-yl)-1-naphthalenyl-methanone |
Some trade or other names: JWH-015; |
(38) (Blank); 4-methoxynaphthalen-1-yl- |
(1-pentylindol-3-yl)methanone |
Some trade or other names: JWH-081; |
(39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole |
Some trade or other names: JWH-122; |
(40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl- |
1H-indol-3-yl)-ethanone |
Some trade or other names: JWH-251; |
(41) (Blank); 1-(2-cyclohexylethyl)-3- |
(2-methoxyphenylacetyl)indole |
Some trade or other names: RCS-8, BTW-8 and SR-18; |
(42) Any compound structurally derived from |
3-(1-naphthoyl)indole or 1H-indol-3-yl- |
(1-naphthyl)methane by substitution at the |
nitrogen atom of the indole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
|
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
or 2-(4-morpholinyl)ethyl whether or not further |
substituted in the indole ring to any extent, whether |
or not substituted in the naphthyl ring to any extent. |
Examples of this structural class include, but are |
not limited to, JWH-018, AM-2201, JWH-175, JWH-184, |
and JWH-185; |
(43) Any compound structurally derived from |
3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
or 2-(4-morpholinyl)ethyl, whether or not further |
substituted in the pyrrole ring to any extent, whether |
or not substituted in the naphthyl ring to any extent. |
Examples of this structural class include, but are not |
limited to, JWH-030, JWH-145, JWH-146, JWH-307, and |
JWH-368; |
(44) Any compound structurally derived from |
1-(1-naphthylmethyl)indene by substitution |
at the 3-position of the indene ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
halide, alkyl aryl halide, 1-(N-methyl- |
2-piperidinyl)methyl, or 2-(4- |
morpholinyl)ethyl whether or not further substituted in |
the indene ring to any extent, whether or not substituted |
|
in the naphthyl ring to any extent. Examples of |
this structural class include, but are not |
limited to, JWH-176; |
(45) Any compound structurally derived from |
3-phenylacetylindole by substitution at the |
nitrogen atom of the indole ring with alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
whether or not further substituted in the indole ring |
to any extent, whether or not substituted in the phenyl |
ring to any extent. Examples of this structural |
class include, but are not limited to, JWH-167, |
JWH-250, JWH-251, and RCS-8; |
(46) Any compound structurally derived from |
2-(3-hydroxycyclohexyl)phenol by substitution |
at the 5-position of the phenolic ring by alkyl, |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
whether or not substituted in the cyclohexyl ring to any |
extent. Examples of this structural class |
include, but are not limited to, CP 47, |
497 and its C8 homologue (cannabicyclohexanol); |
(46.1) Any compound structurally |
derived from Benzoylindoles: Any compound |
|
containing a 3-(benzoyl) indole structure with |
substitution at the nitrogen atom of the |
indole ring by an alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, |
or 2-(4-morpholinyl)ethyl group |
whether or not further substituted |
in the indole ring to any extent and |
whether or not substituted in the phenyl ring |
to any extent. Examples of this structural class |
include, but are not limited, to, AM-630, |
AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
(47) (Blank); 3,4-Methylenedioxymethcathinone |
Some trade or other names: Methylone; |
(48) (Blank); 3,4-Methyenedioxypyrovalerone |
Some trade or other names: MDPV; |
(49) (Blank); 4-Methylmethcathinone |
Some trade or other names: Mephedrone; |
(50) (Blank); 4-methoxymethcathinone; |
(51) (Blank); 4-Fluoromethcathinone; |
(52) (Blank); 3-Fluoromethcathinone; |
(53) 2,5-Dimethoxy-4-(n)-propylthio- |
phenethylamine; |
Some trade or other names: 2C-T-7; |
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine |
|
Some trade or other names: 2C-E; |
(53.2) 2,5-dimethoxy-4-methylphenethylamine |
Some trade or other names: 2C-D; |
(53.3) 4-chloro-2,5-dimethoxyphenethylamine |
Some trade or other names: 2C-C; |
(53.4) 4-iodo-2,5-dimethoxyphenethylamine |
Some trade or other names: 2C-I; |
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine |
Some trade or other names: 2C-T-2; |
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine |
Some trade or other names: 2C-T-4; |
(53.7) 2,5-dimethoxyphenethylamine |
Some trade or other names: 2C-H; |
(53.8) 2,5-dimethoxy-4-nitrophenethylamine |
Some trade or other names: 2C-N; |
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine |
Some trade or other names: 2C-P; |
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine |
Some trade or other names: 2C-G; |
(53.11) The N-(2-methoxybenzyl) derivative of any 2C |
phenethylamine referred to in subparagraphs (20.1), (53), |
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), |
(53.8), (53.9), and (53.10) including, but not limited to, |
25I-NBOMe and 25C-NBOMe; |
(54) 5-Methoxy-N,N-diisopropyltryptamine; |
(55) (Blank); Pentedrone; |
|
(56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy |
phenyl)methyl)-benzeneethanamine |
(trade or other name: 25I-NBOMe); |
(57) (Blank); 4-chloro-2,5-dimethoxy- |
N-[(2-methoxyphenyl) methyl]-benzeneethanamine |
(trade or other name: 25C-NBOMe); |
(58) (Blank); 4-bromo-2,5-dimethoxy |
-N-[(2-methoxyphenyl) methyl]-benzeneethanamine |
(trade or other name: 25B-NBOMe); |
(59) 3-cyclopropoylindole with |
substitution at the nitrogen atom of the |
indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl |
halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not |
further substituted on the indole ring |
to any extent, whether or not substituted |
on the cyclopropyl ring to any extent: |
including, but not limited to, XLR11, |
UR144, FUB-144; |
(60) 3-adamantoylindole with |
substitution at the nitrogen atom of the |
indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, |
|
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not |
further substituted on the indole ring to |
any extent, whether or not substituted on |
the adamantyl ring to any extent: including, |
but not limited to, AB-001; |
(61) N-(adamantyl)-indole-3-carboxamide |
with substitution at the nitrogen atom of the |
indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, |
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
or 2-(4-morpholinyl)ethyl, whether or not further |
substituted on the indole ring to any extent, whether |
or not substituted on the adamantyl ring to any |
extent: including, but not limited to, |
APICA/2NE-1, STS-135; |
(62) N-(adamantyl)-indazole-3-carboxamide |
with substitution at a nitrogen atom of the indazole |
ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
cycloalkylethyl, aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further |
substituted on the indazole ring to any extent, |
whether or not substituted on the adamantyl |
ring to any extent: including, but not limited |
to, AKB48, 5F-AKB48; |
|
(63) 1H-indole-3-carboxylic acid 8-quinolinyl |
ester with substitution at the nitrogen atom of the |
indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further |
substituted on the indole ring to any extent, |
whether or not substituted on the quinoline ring |
to any extent: including, but not limited to, PB22, |
5F-PB22, FUB-PB-22; |
(64) 3-(1-naphthoyl)indazole with |
substitution at the nitrogen atom of the |
indazole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further |
substituted on the indazole ring to any extent, |
whether or not substituted on the naphthyl ring |
to any extent: including, but not limited to, |
THJ-018, THJ-2201; |
(65) 2-(1-naphthoyl)benzimidazole with |
substitution at the nitrogen atom of the benzimidazole |
ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
cycloalkylethyl, aryl halide, alkyl aryl halide, |
1-(N-methyl-2-piperidinyl)methyl, or |
|
2-(4-morpholinyl)ethyl, whether or not further |
substituted on the benzimidazole ring to any extent, |
whether or not substituted on the naphthyl ring to |
any extent: including, but not limited to, FUBIMINA; |
(66) N-(1-amino-3-methyl-1-oxobutan-2-yl) |
-1H-indazole-3-carboxamide with substitution on the |
nitrogen atom of the indazole ring by alkyl, |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
whether or not further substituted on the indazole |
ring to any extent: including, but not limited to, |
AB-PINACA, AB-FUBINACA, AB-CHMINACA; |
(67) N-(1-amino-3,3-dimethyl-1-oxobutan- |
2-yl)-1H-indazole-3-carboxamide with substitution |
on the nitrogen atom of the indazole ring by alkyl, |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether |
or not further substituted on the indazole ring to any |
extent: including, but not limited to, ADB-PINACA, |
ADB-FUBINACA; |
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- |
1H-indole-3-carboxamide with substitution on the nitrogen |
atom of the indole ring by alkyl, haloalkyl, alkenyl, |
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
|
aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2-(4-morpholinyl)ethyl, whether or not further |
substituted on the indole ring to any extent: |
including, but not limited to, ADBICA, 5F-ADBICA; |
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- |
1H-indole-3-carboxamide with substitution on the |
nitrogen atom of the indole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
whether or not further substituted on the indole |
ring to any extent: including, but not limited |
to, ABICA, 5F-ABICA; |
(70) Methyl 2-(1H-indazole-3-carboxamido)- |
3-methylbutanoate with substitution on the nitrogen |
atom of the indazole ring by alkyl, haloalkyl, |
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
halide, alkyl aryl halide, 1-(N-methyl-2- |
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
whether or not further substituted on the indazole |
ring to any extent: including, but not limited to, AMB, |
5F-AMB. |
(71) Methyl 2-(1H-indazole-3-carboxamido)
|
-3,3-dimethylbutanoate with substitution on the nitrogen
|
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
|
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
|
|
aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
|
(4-morpholinyl)ethyl, whether or not further substituted
|
on the indazole ring to any extent: including, but not
|
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; |
(72) Methyl 2-(1H-indole-3-carboxamido)-
|
3-methylbutanoate with substitution on the nitrogen atom
|
of the indole ring by alkyl, haloalkyl, alkenyl,
|
cycloalkylmethyl, cycloalkylethyl, aryl halide,
|
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
|
or 2-(4-morpholinyl)ethyl, whether or not further
|
substituted on the indazole ring to any extent:
|
including, but not limited to, MMB018, MMB2201,
|
and AMB-CHMICA; |
(73) Methyl 2-(1H-indole-3-
|
carboxamido)-3,3-dimethylbutanoate with substitution
|
on the nitrogen atom of the indole ring by alkyl,
|
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
|
aryl halide, alkyl aryl halide, 1-(N-methyl-2-
|
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
|
whether or not further substituted on the
|
indazole ring to any extent: including, but
|
not limited to, MDMB-CHMICA; |
(74) N-(1-Amino-1-oxo-3-phenylpropan
|
-2-yl) -1H-indazole-3-carboxamide with
|
substitution on the nitrogen atom of the indazole
|
ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
|
|
cycloalkylethyl, aryl halide, alkyl aryl halide,
|
1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
|
morpholinyl)ethyl, whether or not further
|
substituted on the indazole ring to any
|
extent: including, but not limited to, APP-CHMINACA,
|
5-fluoro-APP-PINACA; |
(75) N-(1-Amino-1-oxo-3-phenylpropan
|
-2-yl)-1H-indole-3-carboxamide with substitution on
|
the nitrogen atom of the indole ring by alkyl,
|
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
|
aryl halide, alkyl aryl halide, 1-(N-methyl-2-
|
piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
|
whether or not further substituted on the indazole
|
ring to any extent: including, but not limited to,
|
APP-PICA and 5-fluoro-APP-PICA; |
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name |
4-AcO-DMT; |
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade |
name 5-MeO-MIPT; |
(78) 4-hydroxy Diethyltryptamine (4-HO-DET); |
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); |
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); |
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
|
(4-HO-MiPT); |
(82) Fluorophenylpiperazine; |
(83) Methoxetamine; |
|
(84) 1-(Ethylamino)-2-phenylpropan-2-
|
one (iso-ethcathinone). |
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a depressant effect on
the central nervous |
system, including its salts, isomers, and salts of
isomers |
whenever the existence of such salts, isomers, and salts of
|
isomers is possible within the specific chemical designation: |
(1) mecloqualone; |
(2) methaqualone; and |
(3) gamma hydroxybutyric acid. |
(f) Unless specifically excepted or unless listed in |
another schedule,
any material, compound, mixture, or |
preparation which contains any quantity
of the following |
substances having a stimulant effect on the central nervous
|
system, including its salts, isomers, and salts of isomers: |
(1) Fenethylline; |
(2) N-ethylamphetamine; |
(3) Aminorex (some other names:
|
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
salts, optical isomers, and salts of optical isomers; |
(4) Methcathinone (some other names:
|
2-methylamino-1-phenylpropan-1-one;
|
Ephedrone; 2-(methylamino)-propiophenone;
|
|
alpha-(methylamino)propiophenone; N-methylcathinone;
|
methycathinone; Monomethylpropion; UR 1431) and its
|
salts, optical isomers, and salts of optical isomers; |
(5) Cathinone (some trade or other names:
|
2-aminopropiophenone; alpha-aminopropiophenone;
|
2-amino-1-phenyl-propanone; norephedrone); |
(6) N,N-dimethylamphetamine (also known as:
|
N,N-alpha-trimethyl-benzeneethanamine;
|
N,N-alpha-trimethylphenethylamine); |
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
(8) 3,4-Methylenedioxypyrovalerone (MDPV); . |
(9) Halogenated amphetamines and
|
methamphetamines – any compound derived from either
|
amphetamine or methamphetamine through the substitution
|
of a halogen on the phenyl ring, including, but not
|
limited to, 2-fluoroamphetamine, 3-
|
fluoroamphetamine and 4-fluoroamphetamine; |
(10) Aminopropylbenzofuran (APB):
|
including 4-(2-Aminopropyl) benzofuran, 5-
|
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
|
benzofuran, and 7-(2-Aminopropyl) benzofuran; |
(11) Aminopropyldihydrobenzofuran (APDB):
|
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
|
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
|
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
|
|
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; |
(12) Methylaminopropylbenzofuran
|
(MAPB): including 4-(2-methylaminopropyl)
|
benzofuran, 5-(2-methylaminopropyl)benzofuran,
|
6-(2-methylaminopropyl)benzofuran
|
and 7-(2-methylaminopropyl)benzofuran. |
(g) Temporary listing of substances subject to emergency |
scheduling.
Any material, compound, mixture, or preparation |
that contains any quantity
of the following substances: |
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
(benzylfentanyl), its optical isomers, isomers, salts,
|
and salts of isomers; |
(2) N-[1(2-thienyl)
|
methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
|
its optical isomers, salts, and salts of isomers. |
(h) Synthetic cathinones. Unless specifically excepted, |
any chemical compound which is not approved by the United |
States Food and Drug Administration or, if approved, is not |
dispensed or possessed in accordance with State or federal law, |
not including bupropion, structurally derived from |
2-aminopropan-1-one by substitution at the 1-position with |
either phenyl, naphthyl, or thiophene ring systems, whether or |
not the compound is further modified in one or more of the |
following ways: |
(1) by substitution in the ring system to |
any extent with alkyl, alkylenedioxy, alkoxy, |
|
haloalkyl, hydroxyl, or halide substituents, whether |
or not further substituted in the ring system |
by one or more other univalent substituents. |
Examples of this class include, but are not |
limited to, 3,4-Methylenedioxycathinone |
(bk-MDA); |
(2) by substitution at the 3-position |
with an acyclic alkyl substituent. Examples of |
this class include, but are not limited to, |
2-methylamino-1-phenylbutan-1-one |
(buphedrone); or |
(3) by substitution at the 2-amino nitrogen |
atom with alkyl, dialkyl, benzyl, or methoxybenzyl |
groups, or by inclusion of the 2-amino nitrogen atom |
in a cyclic structure. Examples of this class include, |
but are not limited to, Dimethylcathinone, Ethcathinone, |
and a-Pyrrolidinopropiophenone (a-PPP). |
(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised |
10-25-16.)
|
(720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
|
Sec. 206. (a) The controlled substances listed in this |
Section are
included in Schedule II.
|
(b) Unless specifically excepted or unless listed in |
another
schedule, any of the following substances whether |
produced directly or
indirectly by extraction from substances |
|
of vegetable origin, or
independently by means of chemical |
synthesis, or by combination of
extraction and chemical |
synthesis:
|
(1) Opium and opiates, and any salt, compound, |
derivative or
preparation of opium or opiate, excluding |
apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, |
nalmefene, naloxone, and naltrexone, and their respective
|
salts, but including the following:
|
(i) Raw Opium;
|
(ii) Opium extracts;
|
(iii) Opium fluid extracts;
|
(iv) Powdered opium;
|
(v) Granulated opium;
|
(vi) Tincture of opium;
|
(vii) Codeine;
|
(viii) Ethylmorphine;
|
(ix) Etorphine Hydrochloride;
|
(x) Hydrocodone;
|
(xi) Hydromorphone;
|
(xii) Metopon;
|
(xiii) Morphine;
|
(xiii.5) 6-Monoacetylmorphine;
|
(xiv) Oxycodone;
|
(xv) Oxymorphone;
|
(xv.5) Tapentadol;
|
(xvi) Thebaine;
|
|
(xvii) Thebaine-derived butorphanol.
|
(xviii) Methorphan Dextromethorphan, except drug |
products containing dextromethorphan that may be |
dispensed pursuant to a prescription order of a |
practitioner and are sold in compliance with the safety |
and labeling standards as set forth by the United |
States Food and Drug Administration, or drug products |
containing dextromethorphan that are sold in solid, |
tablet, liquid, capsule, powder, thin film, or gel form |
and which are formulated, packaged, and sold in dosages |
and concentrations for use as an over-the-counter drug |
product. For the purposes of this Section, |
"over-the-counter drug product" means a drug that is |
available to consumers without a prescription and sold |
in compliance with the safety and labeling standards as |
set forth by the United States Food and Drug |
Administration.
|
(2) Any salt, compound, isomer, derivative or |
preparation thereof
which is chemically equivalent or |
identical with any of the substances
referred to in |
subparagraph (1), but not including the isoquinoline
|
alkaloids of opium;
|
(3) Opium poppy and poppy straw;
|
(4) Coca leaves and any salt, compound, isomer, salt of |
an isomer,
derivative, or preparation of coca leaves |
including cocaine or ecgonine,
and any salt, compound, |
|
isomer, derivative, or preparation thereof which is
|
chemically equivalent or identical with any of these |
substances, but not
including decocainized coca leaves or |
extractions of coca leaves which do
not contain cocaine or |
ecgonine (for the purpose of this paragraph, the
term |
"isomer" includes optical, positional and geometric |
isomers);
|
(5) Concentrate of poppy straw (the crude extract of |
poppy straw in
either liquid, solid or powder form which |
contains the phenanthrine
alkaloids of the opium poppy).
|
(c) Unless specifically excepted or unless listed in |
another
schedule any of the following opiates, including their |
isomers, esters,
ethers, salts, and salts of isomers, whenever |
the existence of these
isomers, esters, ethers and salts is |
possible within the specific
chemical designation, dextrorphan |
excepted:
|
(1) Alfentanil;
|
(1.1) Carfentanil;
|
(1.2) Thiafentanyl;
|
(2) Alphaprodine;
|
(3) Anileridine;
|
(4) Bezitramide;
|
(5) Bulk Dextropropoxyphene (non-dosage forms);
|
(6) Dihydrocodeine;
|
(7) Diphenoxylate;
|
(8) Fentanyl;
|
|
(9) Sufentanil;
|
(9.5) Remifentanil;
|
(10) Isomethadone;
|
(11) (Blank); Levomethorphan;
|
(12) Levorphanol (Levorphan);
|
(13) Metazocine;
|
(14) Methadone;
|
(15) Methadone-Intermediate,
|
4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
|
(16) Moramide-Intermediate,
|
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
|
acid;
|
(17) Pethidine (meperidine);
|
(18) Pethidine-Intermediate-A,
|
4-cyano-1-methyl-4-phenylpiperidine;
|
(19) Pethidine-Intermediate-B,
|
ethyl-4-phenylpiperidine-4-carboxylate;
|
(20) Pethidine-Intermediate-C,
|
1-methyl-4-phenylpiperidine-4-carboxylic acid;
|
(21) Phenazocine;
|
(22) Piminodine;
|
(23) Racemethorphan;
|
(24) (Blank); Racemorphan;
|
(25) Levo-alphacetylmethadol (some other names:
|
levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
|
(d) Unless specifically excepted or unless listed in |
|
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a stimulant effect on
the central nervous |
system:
|
(1) Amphetamine, its salts, optical isomers, and salts |
of its
optical isomers;
|
(2) Methamphetamine, its salts, isomers, and salts of |
its isomers;
|
(3) Phenmetrazine and its salts;
|
(4) Methylphenidate;
|
(5) Lisdexamfetamine. |
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a depressant effect on
the central nervous |
system, including its salts, isomers, and salts of
isomers |
whenever the existence of such salts, isomers, and salts of
|
isomers is possible within the specific chemical designation:
|
(1) Amobarbital;
|
(2) Secobarbital;
|
(3) Pentobarbital;
|
(4) Pentazocine;
|
(5) Phencyclidine;
|
(6) Gluthethimide;
|
(7) (Blank).
|
(f) Unless specifically excepted or unless listed in |
|
another schedule,
any material, compound, mixture, or |
preparation which contains any quantity
of the following |
substances:
|
(1) Immediate precursor to amphetamine and |
methamphetamine:
|
(i) Phenylacetone
|
Some trade or other names: phenyl-2-propanone;
|
P2P; benzyl methyl ketone; methyl benzyl ketone.
|
(2) Immediate precursors to phencyclidine:
|
(i) 1-phenylcyclohexylamine;
|
(ii) 1-piperidinocyclohexanecarbonitrile (PCC).
|
(3) Nabilone.
|
(Source: P.A. 97-334, eff. 1-1-12.)
|
(720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
|
Sec. 208.
(a) The controlled substances listed in this |
Section are
included in Schedule III.
|
(b) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a stimulant effect on
the central nervous |
system, including its salts, isomers (whether
optical |
position, or geometric), and salts of such isomers whenever the
|
existence of such salts, isomers, and salts of isomers is |
possible
within the specific chemical designation;
|
(1) Those compounds, mixtures, or preparations in |
|
dosage unit form
containing any stimulant substances |
listed in Schedule II which
compounds, mixtures, or |
preparations were listed on August 25, 1971, as
excepted |
compounds under Title 21, Code of Federal Regulations, |
Section
308.32, and any other drug of the quantitative |
composition shown in that
list for those drugs or which is |
the same except that it contains a
lesser quantity of |
controlled substances;
|
(2) Benzphetamine;
|
(3) Chlorphentermine;
|
(4) Clortermine;
|
(5) Phendimetrazine.
|
(c) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a potential for abuse
associated with a |
depressant effect on the central nervous system:
|
(1) Any compound, mixture, or preparation containing |
amobarbital,
secobarbital, pentobarbital or any salt |
thereof and one or more other
active medicinal ingredients |
which are not listed in any schedule;
|
(2) Any suppository dosage form containing |
amobarbital,
secobarbital, pentobarbital or any salt of |
any of these drugs and
approved by the Federal Food and |
Drug Administration for marketing only
as a suppository;
|
(3) Any substance which contains any quantity of a |
|
derivative of
barbituric acid, or any salt thereof:
|
(3.1) Aprobarbital; |
(3.2) Butabarbital (secbutabarbital); |
(3.3) Butalbital; |
(3.4) Butobarbital (butethal);
|
(4) Chlorhexadol;
|
(5) Methyprylon;
|
(6) Sulfondiethylmethane;
|
(7) Sulfonethylmethane;
|
(8) Sulfonmethane;
|
(9) Lysergic acid;
|
(10) Lysergic acid amide;
|
(10.1) Tiletamine or zolazepam or both, or any salt of |
either of them.
|
Some trade or other names for a tiletamine-zolazepam
|
combination product: Telazol.
|
Some trade or other names for Tiletamine:
|
2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
|
Some trade or other names for zolazepam:
|
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
|
[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
|
(11) Any material, compound, mixture or preparation |
containing not more
than 12.5 milligrams of pentazocine or |
any of its salts, per 325 milligrams of
aspirin;
|
(12) Any material, compound, mixture or preparation |
containing not
more than 12.5 milligrams of pentazocine or |
|
any of its salts, per 325
milligrams of acetaminophen;
|
(13) Any material, compound, mixture or preparation |
containing not more
than 50 milligrams of pentazocine or |
any of its salts plus naloxone HCl USP
0.5 milligrams, per |
dosage unit;
|
(14) Ketamine;
|
(15) Thiopental. |
(d) Nalorphine.
|
(d.5) Buprenorphine. |
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation containing
limited quantities of any of the |
following narcotic drugs, or their salts
calculated as the free |
anhydrous base or alkaloid, as set forth below:
|
(1) not more than 1.8 grams of codeine per 100
|
milliliters or not more than 90 milligrams per dosage unit, |
with an
equal or greater quantity of an isoquinoline |
alkaloid of opium;
|
(2) not more than 1.8 grams of codeine per 100
|
milliliters or not more than 90 milligrams per dosage unit, |
with one or
more active non-narcotic ingredients in |
recognized therapeutic amounts;
|
(3) (blank); not more than 300 milligrams of |
dihydrocodeinone per 100 milliliters
or not more than 15 |
milligrams per dosage
unit, with a fourfold or greater |
quantity of an isoquinoline alkaloid of
opium;
|
|
(4) (blank); not more than 300 milligrams of |
dihydrocodeinone per 100 milliliters
or not more than 15 |
milligrams per dosage
unit, with one or more active, |
non-narcotic ingredients in recognized
therapeutic |
amounts;
|
(5) not more than 1.8 grams of dihydrocodeine
per 100 |
milliliters or not more than 90 milligrams per dosage unit, |
with
one or more active, non-narcotic ingredients in |
recognized therapeutic
amounts;
|
(6) not more than 300 milligrams of ethylmorphine per |
100 milliliters
or not more than 15 milligrams per dosage
|
unit, with one or more active, non-narcotic ingredients in |
recognized
therapeutic amounts;
|
(7) not more than 500 milligrams of opium per 100 |
milliliters or per
100 grams, or not more than 25 |
milligrams per dosage unit, with one or
more active, |
non-narcotic ingredients in recognized therapeutic |
amounts;
|
(8) not more than 50 milligrams of morphine
per 100 |
milliliters or per 100 grams with one or more active,
|
non-narcotic ingredients in recognized therapeutic |
amounts.
|
(f) Anabolic steroids, except the following anabolic |
steroids that are
exempt:
|
(1) Androgyn L.A.;
|
(2) Andro-Estro 90-4;
|
|
(3) depANDROGYN;
|
(4) DEPO-T.E.;
|
(5) depTESTROGEN;
|
(6) Duomone;
|
(7) DURATESTRIN;
|
(8) DUO-SPAN II;
|
(9) Estratest;
|
(10) Estratest H.S.;
|
(11) PAN ESTRA TEST;
|
(12) Premarin with Methyltestosterone;
|
(13) TEST-ESTRO Cypionates;
|
(14) Testosterone Cyp 50 Estradiol Cyp 2;
|
(15) Testosterone Cypionate-Estradiol Cypionate |
injection; and
|
(16) Testosterone Enanthate-Estradiol Valerate |
injection.
|
(g) Hallucinogenic
substances.
|
(1) Dronabinol (synthetic) in sesame oil and |
encapsulated in a soft
gelatin capsule in a U.S.
Food and |
Drug Administration approved product. Some other names for
|
dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
|
6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)
pyran-1-ol) or |
(-)-delta-9-(trans)-tetrahydrocannabinol.
|
(2) (Reserved).
|
(h) The Department may except by rule any compound, |
mixture, or
preparation containing any stimulant or depressant |
|
substance listed in
subsection (b) from the application of all |
or any part of this
Act if the compound, mixture, or |
preparation contains one or more active
medicinal ingredients |
not having a stimulant or depressant effect on the
central |
nervous system, and if the admixtures are included therein in
|
combinations, quantity, proportion, or concentration that |
vitiate the
potential for abuse of the substances which have a |
stimulant or
depressant effect on the central nervous system.
|
(Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; |
97-334, eff. 1-1-12.)
|
(720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
|
Sec. 401. Manufacture or delivery, or possession with |
intent to
manufacture or deliver, a controlled substance, a |
counterfeit substance, or controlled substance analog. Except |
as authorized by this Act, it is unlawful for any
person |
knowingly to manufacture or deliver, or possess with intent to
|
manufacture or deliver, a controlled substance other than |
methamphetamine and other than bath salts as defined in the |
Bath Salts Prohibition Act sold or offered for sale in a retail |
mercantile establishment as defined in Section 16-0.1 of the |
Criminal Code of 2012, a counterfeit substance, or a controlled
|
substance analog. A violation of this Act with respect to each |
of the controlled
substances listed herein constitutes a single |
and separate violation of this
Act. For purposes of this |
Section, "controlled substance analog" or "analog"
means a |
|
substance, other than a controlled substance, which is not |
approved by the United States Food and Drug Administration or, |
if approved, is not dispensed or possessed in accordance with |
State or federal law, and that has a chemical structure |
substantially similar to that of a controlled
substance in |
Schedule I or II, or that was specifically designed to produce
|
an effect substantially similar to that of a controlled |
substance in Schedule
I or II. Examples of chemical classes in |
which controlled substance analogs
are found include, but are |
not limited to, the following: phenethylamines,
N-substituted |
piperidines, morphinans, ecgonines, quinazolinones, |
substituted
indoles, and arylcycloalkylamines. For purposes of |
this Act, a controlled
substance analog shall be treated in the |
same manner as the controlled
substance to which it is |
substantially similar.
|
(a) Any person who violates this Section with respect to |
the following
amounts of controlled or counterfeit substances |
or controlled substance
analogs, notwithstanding any of the |
provisions of subsections (c),
(d), (e), (f), (g) or (h) to the |
contrary, is guilty of a Class X felony
and shall be sentenced |
to a term of imprisonment as provided in this subsection
(a) |
and fined as provided in subsection (b):
|
(1) (A) not less than 6 years and not more than 30 |
years with respect
to 15 grams or more but less than |
100 grams of a substance containing
heroin, or an |
analog thereof;
|
|
(B) not less than 9 years and not more than 40 |
years with respect to 100
grams or more but less than |
400 grams of a substance containing heroin, or
an |
analog thereof;
|
(C) not less than 12 years and not more than 50 |
years with respect to
400 grams or more but less than |
900 grams of a substance containing heroin,
or an |
analog thereof;
|
(D) not less than 15 years and not more than 60 |
years with respect to
900 grams or more of any |
substance containing heroin, or an analog thereof;
|
(1.5) (A) not less than 6 years and not more than 30 |
years with respect to 15 grams or more but less than |
100 grams of a substance containing fentanyl, or an |
analog thereof; |
(B) not less than 9 years and not more than 40 |
years with respect to 100 grams or more but less than |
400 grams of a substance containing fentanyl, or an |
analog thereof; |
(C) not less than 12 years and not more than 50 |
years with respect to 400 grams or more but less than |
900 grams of a substance containing fentanyl, or an |
analog thereof; |
(D) not less than 15 years and not more than 60 |
years with respect to 900 grams or more of a substance |
containing fentanyl, or an analog thereof; |
|
(2) (A) not less than 6 years and not more than 30 |
years with respect
to 15 grams or more but less than |
100 grams of a substance containing
cocaine, or an |
analog thereof;
|
(B) not less than 9 years and not more than 40 |
years with respect to 100
grams or more but less than |
400 grams of a substance containing cocaine, or
an |
analog thereof;
|
(C) not less than 12 years and not more than 50 |
years with respect to
400 grams or more but less than |
900 grams of a substance containing cocaine,
or an |
analog thereof;
|
(D) not less than 15 years and not more than 60 |
years with respect to
900 grams or more of any |
substance containing cocaine, or an analog thereof;
|
(3) (A) not less than 6 years and not more than 30 |
years with respect
to 15 grams or more but less than |
100 grams of a substance containing
morphine, or an |
analog thereof;
|
(B) not less than 9 years and not more than 40 |
years with respect to
100 grams or more but less than |
400 grams of a substance containing morphine,
or an |
analog thereof;
|
(C) not less than 12 years and not more than 50 |
years with respect to
400 grams or more but less than |
900 grams of a substance containing
morphine, or an |
|
analog thereof;
|
(D) not less than 15 years and not more than 60 |
years with respect to
900 grams or more of a substance |
containing morphine, or an analog thereof;
|
(4) 200 grams or more of any substance containing |
peyote, or an
analog thereof;
|
(5) 200 grams or more of any substance containing a |
derivative of
barbituric acid or any of the salts of a |
derivative of barbituric acid, or
an analog thereof;
|
(6) 200 grams or more of any substance containing |
amphetamine
or any salt of an optical isomer of |
amphetamine,
or an analog thereof;
|
(6.5) (blank);
|
(6.6) (blank);
|
(7) (A) not less than 6 years and not more than 30 |
years with respect
to: (i) 15 grams or more but less |
than 100 grams of a substance containing
lysergic acid |
diethylamide (LSD), or an analog thereof, or (ii) 15 or
|
more objects or 15 or more segregated parts of an |
object or objects but
less than 200 objects or 200 |
segregated parts of an object or objects
containing in |
them or having upon them any amounts of any substance
|
containing lysergic acid diethylamide (LSD), or an |
analog thereof;
|
(B) not less than 9 years and not more than 40 |
years with respect
to: (i) 100 grams or more but less |
|
than 400 grams of a substance containing
lysergic acid |
diethylamide (LSD), or an analog thereof, or (ii) 200 |
or more
objects or 200 or more segregated parts of an |
object or objects but less
than 600 objects or less |
than 600 segregated parts of an object or objects
|
containing in them or having upon them any amount of |
any substance
containing lysergic acid diethylamide |
(LSD), or an analog thereof;
|
(C) not less than 12 years and not more than 50 |
years with respect
to: (i) 400 grams or more but less |
than 900 grams of a substance containing
lysergic acid |
diethylamide (LSD), or an analog thereof, or (ii) 600 |
or more
objects or 600 or more segregated parts of an |
object or objects but less
than 1500 objects or 1500 |
segregated parts of an object or objects
containing in |
them or having upon them any amount of any substance
|
containing lysergic acid diethylamide (LSD), or an |
analog thereof;
|
(D) not less than 15 years and not more than 60 |
years with respect
to: (i) 900 grams or more of any |
substance containing lysergic acid
diethylamide (LSD), |
or an analog thereof, or (ii) 1500 or more objects or
|
1500 or more segregated parts of an object or objects |
containing in them or
having upon them any amount of a |
substance containing lysergic acid
diethylamide (LSD), |
or an analog thereof;
|
|
(7.5) (A) not less than 6 years and not more than 30 |
years with respect
to:
(i) 15
grams or more but less |
than 100 grams of a substance listed in paragraph (1),
|
(2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), |
(21), (25), or (26) of subsection
(d) of Section 204, |
or an analog or derivative thereof, or (ii) 15 or more
|
pills, tablets, caplets, capsules, or objects but less |
than 200 pills, tablets,
caplets, capsules, or objects |
containing in them or having upon them any
amounts of |
any substance listed in paragraph (1), (2), (2.1), |
(2.2), (3), (14.1),
(19), (20), (20.1), (21), (25), or |
(26) of subsection (d) of Section 204, or
an analog or |
derivative thereof;
|
(B) not less than 9 years and not more than 40 |
years with respect to:
(i) 100 grams or more but less |
than 400 grams of a substance listed in
paragraph (1), |
(2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), |
(21), (25), or (26) of subsection (d) of Section 204, |
or an analog or
derivative thereof, or (ii) 200 or more |
pills, tablets, caplets, capsules, or
objects but less |
than 600 pills, tablets, caplets, capsules, or objects
|
containing in them or having upon them any amount of |
any substance listed in
paragraph (1), (2), (2.1), |
(2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or |
(26)
of subsection (d) of Section 204, or an analog or |
derivative thereof;
|
|
(C) not less than 12 years and not more than 50 |
years with respect to:
(i) 400 grams or more but less |
than 900 grams of a substance listed in
paragraph (1), |
(2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), |
(21), (25), or (26)
of subsection (d) of Section 204, |
or an analog or derivative thereof,
or (ii) 600 or more |
pills, tablets, caplets, capsules, or objects but less |
than
1,500 pills, tablets, caplets, capsules, or |
objects
containing in them or having upon them any |
amount of any substance listed in
paragraph (1), (2), |
(2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21), |
(25), or (26)
of subsection (d) of Section 204, or an |
analog or derivative thereof;
|
(D) not less than 15 years and not more than 60 |
years with respect to:
(i) 900 grams or more of any |
substance listed in paragraph (1), (2), (2.1),
(2.2), |
(3), (14.1), (19), (20), (20.1), (21), (25), or (26) of |
subsection (d) of
Section 204, or an analog or |
derivative thereof, or (ii) 1,500 or more pills,
|
tablets, caplets, capsules, or objects containing in |
them or having upon them
any amount
of a substance |
listed in paragraph (1), (2), (2.1), (2.2), (3), |
(14.1), (19),
(20), (20.1), (21), (25), or (26)
of |
subsection (d) of Section 204, or an analog or |
derivative thereof;
|
(8) 30 grams or more of any substance containing |
|
pentazocine or any of
the salts, isomers and salts of |
isomers of pentazocine, or an analog thereof;
|
(9) 30 grams or more of any substance containing |
methaqualone or any of
the salts, isomers and salts of |
isomers of methaqualone, or an analog thereof;
|
(10) 30 grams or more of any substance containing |
phencyclidine or any
of the salts, isomers and salts of |
isomers of phencyclidine (PCP),
or an analog thereof;
|
(10.5) 30 grams or more of any substance containing |
ketamine
or any of the salts, isomers and salts of isomers |
of ketamine,
or an analog thereof;
|
(10.6) 100 grams or more of any substance containing |
hydrocodone, or any of the salts, isomers and salts of |
isomers of hydrocodone, or an analog thereof; |
(10.7) (blank); 100 grams or more of any substance |
containing dihydrocodeinone, or any of the salts, isomers |
and salts of isomers of dihydrocodeinone, or an analog |
thereof; |
(10.8) 100 grams or more of any substance containing |
dihydrocodeine, or any of the salts, isomers and salts of |
isomers of dihydrocodeine, or an analog thereof; |
(10.9) 100 grams or more of any substance containing |
oxycodone, or any of the salts, isomers and salts of |
isomers of oxycodone, or an analog thereof; |
(11) 200 grams or more of any substance containing any |
other controlled
substance classified in Schedules I or II, |
|
or an analog thereof, which is
not otherwise included in |
this subsection.
|
(b) Any person sentenced with respect to violations of |
paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) |
involving
100 grams or
more of the
controlled substance named |
therein, may in addition to the penalties
provided therein, be |
fined an amount not more than $500,000 or the full
street value |
of the controlled or counterfeit substance or controlled |
substance
analog, whichever is greater. The term "street value" |
shall have the
meaning ascribed in Section 110-5 of the Code of |
Criminal Procedure of
1963. Any person sentenced with respect |
to any other provision of
subsection (a), may in addition to |
the penalties provided therein, be fined
an amount not to |
exceed $500,000. |
(b-1) Excluding violations of this Act when the controlled |
substance is fentanyl, any person sentenced to a term of |
imprisonment with respect to violations of Section 401, 401.1, |
405, 405.1, 405.2, or 407, when the substance containing the |
controlled substance contains any amount of fentanyl, 3 years |
shall be added to the term of imprisonment imposed by the |
court, and the maximum sentence for the offense shall be |
increased by 3 years.
|
(c) Any person who violates this Section with regard to the
|
following amounts of controlled or counterfeit substances
or |
controlled substance analogs, notwithstanding any of the |
provisions of
subsections (a), (b), (d), (e), (f), (g) or (h) |
|
to the
contrary, is guilty of a Class 1 felony. The fine for |
violation of this
subsection (c) shall not be more than |
$250,000:
|
(1) 1 gram or more but less than 15 grams of any
|
substance containing heroin, or an analog thereof;
|
(1.5) 1 gram or more but less than 15 grams of any |
substance containing fentanyl, or an analog thereof; |
(2) 1 gram or more but less than 15
grams of any |
substance containing cocaine, or an analog thereof;
|
(3) 10 grams or more but less than 15 grams of any |
substance
containing morphine, or an analog thereof;
|
(4) 50 grams or more but less than 200 grams of any |
substance
containing peyote, or an analog thereof;
|
(5) 50 grams or more but less than 200 grams of any |
substance
containing a derivative of barbituric acid or any |
of the salts of a
derivative of barbituric acid, or an |
analog thereof;
|
(6) 50 grams or more but less than 200 grams of any |
substance
containing amphetamine or any salt of an optical |
isomer
of amphetamine, or an analog thereof;
|
(6.5) (blank);
|
(7) (i) 5 grams or more but less than 15 grams of any |
substance
containing lysergic acid diethylamide (LSD), or |
an analog thereof,
or (ii)
more than 10 objects or more |
than 10 segregated parts of an object or objects
but less |
than 15 objects or less than 15 segregated parts of an |
|
object
containing in them or having upon them any amount of |
any substance
containing lysergic acid diethylamide (LSD), |
or an analog thereof;
|
(7.5) (i) 5 grams or more but less than 15 grams of any |
substance listed
in paragraph (1), (2), (2.1), (2.2), (3), |
(14.1), (19), (20), (20.1), (21), (25), or
(26) of |
subsection (d) of Section 204, or an analog or derivative |
thereof, or
(ii) more than 10 pills, tablets, caplets, |
capsules, or objects but less than
15 pills, tablets, |
caplets, capsules, or objects containing in them or having
|
upon them any amount of any substance listed in paragraph |
(1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), |
(21), (25), or (26) of subsection (d) of
Section 204, or an |
analog or derivative thereof;
|
(8) 10 grams or more but less than 30 grams of any |
substance
containing pentazocine or any of the salts, |
isomers and salts of isomers of
pentazocine, or an analog |
thereof;
|
(9) 10 grams or more but less than 30 grams of any |
substance
containing methaqualone or any of the salts, |
isomers and salts of isomers
of methaqualone, or an analog |
thereof;
|
(10) 10 grams or more but less than 30 grams of any |
substance
containing phencyclidine or any of the salts, |
isomers and salts of isomers
of phencyclidine (PCP), or an |
analog thereof;
|
|
(10.5) 10 grams or more but less than 30 grams of any |
substance
containing ketamine or any of the salts, isomers |
and salts of
isomers of ketamine, or an analog thereof;
|
(10.6) 50 grams or more but less than 100 grams of any |
substance containing hydrocodone, or any of the salts, |
isomers and salts of isomers of hydrocodone, or an analog |
thereof; |
(10.7) (blank); 50 grams or more but less than 100 |
grams of any substance containing dihydrocodeinone, or any |
of the salts, isomers and salts of isomers of |
dihydrocodeinone, or an analog thereof; |
(10.8) 50 grams or more but less than 100 grams of any |
substance containing dihydrocodeine, or any of the salts, |
isomers and salts of isomers of dihydrocodeine, or an |
analog thereof; |
(10.9) 50 grams or more but less than 100 grams of any |
substance containing oxycodone, or any of the salts, |
isomers and salts of isomers of oxycodone, or an analog |
thereof; |
(11) 50 grams or more but less than 200 grams of any |
substance
containing a substance classified in Schedules I |
or II, or an analog
thereof, which is not otherwise |
included in this subsection.
|
(c-5) (Blank).
|
(d) Any person who violates this Section with regard to any |
other
amount of a controlled or counterfeit substance |
|
containing dihydrocodeinone or dihydrocodeine or classified in
|
Schedules I or II, or an analog thereof, which is (i) a |
narcotic
drug, (ii) lysergic acid diethylamide (LSD) or an |
analog thereof,
(iii) any
substance containing amphetamine or |
fentanyl or any salt or optical
isomer of amphetamine or |
fentanyl, or an analog thereof, or (iv) any
substance |
containing N-Benzylpiperazine (BZP) or any salt or optical
|
isomer of N-Benzylpiperazine (BZP), or an analog thereof, is |
guilty
of a Class 2 felony. The fine for violation of this |
subsection (d) shall
not be more than $200,000.
|
(d-5) (Blank).
|
(e) Any person who violates this Section with regard to any |
other
amount of a controlled substance other than |
methamphetamine or counterfeit substance classified in
|
Schedule I or II, or an analog thereof, which substance is not
|
included under subsection (d) of this Section, is
guilty of a |
Class 3 felony. The fine for violation of this subsection (e)
|
shall not be more than $150,000.
|
(f) Any person who violates this Section with regard to any |
other
amount of a controlled or counterfeit substance |
classified in
Schedule III is guilty of a Class 3 felony. The |
fine for violation of
this subsection (f) shall not be more |
than $125,000.
|
(g) Any person who violates this Section with regard to any |
other
amount of a controlled or counterfeit substance |
classified
in Schedule IV is guilty of a Class 3 felony. The |
|
fine for violation of
this subsection (g) shall not be more |
than $100,000.
|
(h) Any person who violates this Section with regard to any |
other
amount of a controlled or counterfeit substance |
classified in
Schedule V is guilty of a Class 3 felony. The |
fine for violation of this
subsection (h) shall not be more |
than $75,000.
|
(i) This Section does not apply to the manufacture, |
possession or
distribution of a substance in conformance with |
the provisions of an approved
new drug application or an |
exemption for investigational use within the
meaning of Section |
505 of the Federal Food, Drug and Cosmetic Act.
|
(j) (Blank).
|
(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)
|
(720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)
|
Sec. 402. Except as otherwise authorized by this Act, it is |
unlawful for
any person knowingly to possess a controlled or |
counterfeit substance or controlled substance analog.
A |
violation of this Act with respect to each of the controlled |
substances
listed herein constitutes a single and separate |
violation of this Act. For purposes of this Section, |
"controlled substance analog" or "analog"
means a substance, |
other than a controlled substance, which is not approved by the |
United States Food and Drug Administration or, if approved, is |
not dispensed or possessed in accordance with State or federal |
|
law, and that has a chemical structure substantially similar to |
that of a controlled
substance in Schedule I or II, or that was |
specifically designed to produce
an effect substantially |
similar to that of a controlled substance in Schedule
I or II. |
Examples of chemical classes in which controlled substance |
analogs
are found include, but are not limited to, the |
following: phenethylamines,
N-substituted piperidines, |
morphinans, ecgonines, quinazolinones, substituted
indoles, |
and arylcycloalkylamines. For purposes of this Act, a |
controlled
substance analog shall be treated in the same manner |
as the controlled
substance to which it is substantially |
similar.
|
(a) Any person who violates this Section with respect to |
the following
controlled or counterfeit substances and |
amounts, notwithstanding any of the
provisions of subsections |
(c) and (d) to the
contrary, is guilty of a Class 1 felony and |
shall, if sentenced to a term
of imprisonment, be sentenced as |
provided in this subsection (a) and fined
as provided in |
subsection (b):
|
(1) (A) not less than 4 years and not more than 15 |
years with respect
to 15 grams or more but less than |
100 grams of a substance containing heroin;
|
(B) not less than 6 years and not more than 30 |
years with respect to 100
grams or more but less than |
400 grams of a substance containing heroin;
|
(C) not less than 8 years and not more than 40 |
|
years with respect to 400
grams or more but less than |
900 grams of any substance containing heroin;
|
(D) not less than 10 years and not more than 50 |
years with respect to
900 grams or more of any |
substance containing heroin;
|
(2) (A) not less than 4 years and not more than 15 |
years with respect
to 15 grams or more but less than |
100 grams of any substance containing
cocaine;
|
(B) not less than 6 years and not more than 30 |
years with respect to 100
grams or more but less than |
400 grams of any substance containing cocaine;
|
(C) not less than 8 years and not more than 40 |
years with respect to 400
grams or more but less than |
900 grams of any substance containing cocaine;
|
(D) not less than 10 years and not more than 50 |
years with respect to
900 grams or more of any |
substance containing cocaine;
|
(3) (A) not less than 4 years and not more than 15 |
years with respect
to 15 grams or more but less than |
100 grams of any substance containing
morphine;
|
(B) not less than 6 years and not more than 30 |
years with respect to 100
grams or more but less than |
400 grams of any substance containing morphine;
|
(C) not less than 6 years and not more than 40 |
years with respect to 400
grams or more but less than |
900 grams of any substance containing morphine;
|
|
(D) not less than 10 years and not more than 50 |
years with respect to
900 grams or more of any |
substance containing morphine;
|
(4) 200 grams or more of any substance containing |
peyote;
|
(5) 200 grams or more of any substance containing a |
derivative of
barbituric acid or any of the salts of a |
derivative of barbituric acid;
|
(6) 200 grams or more of any substance containing |
amphetamine or any salt
of an optical isomer of |
amphetamine;
|
(6.5) (blank);
|
(7) (A) not less than 4 years and not more than 15 |
years with respect
to: (i) 15 grams or more but less |
than 100 grams of any substance containing
lysergic |
acid diethylamide (LSD), or an analog thereof, or (ii) |
15 or
more objects or 15 or more segregated parts of an |
object or objects but
less than 200 objects or 200 |
segregated parts of an object or objects
containing in |
them or having upon them any amount of any substance
|
containing lysergic acid diethylamide (LSD), or an |
analog thereof;
|
(B) not less than 6 years and not more than 30 |
years with respect
to: (i) 100 grams or more but less |
than 400 grams of any substance
containing lysergic |
acid diethylamide (LSD), or an analog thereof, or (ii)
|
|
200 or more objects or 200 or more segregated parts of |
an object or objects
but less than 600 objects or less |
than 600 segregated parts of an object or
objects |
containing in them or having upon them any amount of |
any substance
containing lysergic acid diethylamide |
(LSD), or an analog thereof;
|
(C) not less than 8 years and not more than 40 |
years with respect
to: (i) 400 grams or more but less |
than 900 grams of any substance
containing lysergic |
acid diethylamide (LSD), or an analog thereof, or (ii)
|
600 or more objects or 600 or more segregated parts of |
an object or objects
but less than 1500 objects or 1500 |
segregated parts of an object or objects
containing in |
them or having upon them any amount of any substance
|
containing lysergic acid diethylamide (LSD), or an |
analog thereof;
|
(D) not less than 10 years and not more than 50 |
years with respect
to: (i) 900 grams or more of any |
substance containing lysergic acid
diethylamide (LSD), |
or an analog thereof, or (ii) 1500 or more objects or
|
1500 or more segregated parts of an object or objects |
containing in them or
having upon them any amount of a |
substance containing lysergic acid
diethylamide (LSD), |
or an analog thereof;
|
(7.5) (A) not less than 4 years and not more than 15 |
years with respect
to: (i) 15
grams or more but
less |
|
than 100 grams of any substance listed in paragraph |
(1), (2), (2.1), (2.2), (3),
(14.1), (19),
(20), |
(20.1), (21), (25), or (26) of subsection (d) of |
Section 204, or an
analog or derivative
thereof, or |
(ii) 15 or more pills, tablets, caplets, capsules, or |
objects but
less than 200 pills,
tablets, caplets, |
capsules, or objects containing in them or having upon |
them
any amount of any
substance listed in paragraph |
(1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
(20.1),
(21), (25), or (26) of
subsection (d) of |
Section 204, or an analog or derivative thereof;
|
(B) not less than 6 years and not more than 30 |
years with respect to: (i)
100
grams or more but
less |
than 400 grams of any substance listed in paragraph |
(1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
|
(20.1), (21), (25), or (26) of subsection (d) of |
Section 204, or an analog or
derivative thereof, or
|
(ii) 200 or more pills, tablets, caplets, capsules, or |
objects but less than
600
pills, tablets,
caplets, |
capsules, or objects containing in them or having upon |
them any amount
of any
substance
listed in paragraph |
(1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
(20.1), (21),
(25), or (26) of subsection
(d) of |
Section 204, or an analog or derivative thereof;
|
(C) not less than 8 years and not more than 40 |
years with respect to: (i)
400
grams or more but
less |
|
than 900 grams of any substance listed in paragraph |
(1), (2), (2.1), (2.2), (3),
(14.1), (19), (20),
|
(20.1), (21), (25), or (26) of subsection (d) of |
Section 204, or an analog or
derivative thereof,
or |
(ii) 600 or more pills, tablets, caplets, capsules, or |
objects but less than
1,500 pills, tablets,
caplets, |
capsules, or objects containing in them or having upon |
them any amount
of any
substance listed in paragraph |
(1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
(20.1),
(21), (25), or (26) of
subsection (d) of |
Section 204, or an analog or derivative thereof;
|
(D) not less than 10 years and not more than 50 |
years with respect to:
(i)
900 grams or more of
any |
substance listed in paragraph (1), (2), (2.1), (2.2), |
(3), (14.1), (19), (20),
(20.1), (21), (25), or (26)
of |
subsection (d) of Section 204, or an analog or |
derivative thereof, or (ii)
1,500 or more pills,
|
tablets, caplets, capsules, or objects containing in |
them or having upon them
any amount of a
substance |
listed in paragraph (1), (2), (2.1), (2.2), (3), |
(14.1), (19), (20), (20.1),
(21), (25), or (26) of
|
subsection (d) of Section 204, or an analog or |
derivative thereof;
|
(8) 30 grams or more of any substance containing |
pentazocine or any of
the salts, isomers and salts of |
isomers of pentazocine, or an analog thereof;
|
|
(9) 30 grams or more of any substance containing |
methaqualone or any
of the salts, isomers and salts of |
isomers of methaqualone;
|
(10) 30 grams or more of any substance containing |
phencyclidine or any
of the salts, isomers and salts of |
isomers of phencyclidine (PCP);
|
(10.5) 30 grams or more of any substance containing |
ketamine or any of
the salts, isomers and salts of isomers |
of ketamine;
|
(11) 200 grams or more of any substance containing any |
substance
classified as a narcotic drug in Schedules I or |
II, or an analog thereof, which is not otherwise
included |
in this subsection.
|
(b) Any person sentenced with respect to violations of |
paragraph (1),
(2), (3), (7), or (7.5) of subsection (a) |
involving 100
grams or more of the
controlled substance named |
therein, may in addition to the penalties
provided therein, be |
fined an amount not to exceed $200,000 or the full
street value |
of the controlled or counterfeit substances, whichever is
|
greater. The term "street value" shall have the meaning
|
ascribed in Section 110-5 of the Code of Criminal Procedure of |
1963. Any
person sentenced with respect to any other provision |
of subsection (a), may
in addition to the penalties provided |
therein, be fined an amount not to
exceed $200,000.
|
(c) Any person who violates this Section with regard to an |
amount
of a controlled substance other than methamphetamine or |
